JTE-013, an S1PR2 antagonist, partially protected against colitis-like pathology in the DSS-induced colitis model [109], and it’s derivatives have been shown to enhance the effects of 5-FU in resistant CRC cell lines [110]. This evidence concerns the gene S1PR2 and colorectal carcinoma.